Mid Atlantic Chapter

T1D Clinical Trials in the Mid-Atlantic Region

Participate in a T1D Clinical Trial

Choosing to participate in a T1D clinical trial is a very personal decision, but one that can have a significant impact on curing, preventing, and treating T1D. Explore additional clinical trial resources from JDRF and our partners at Beyond Type 1 to learn more about clinical trials and their phases.

Check out this video series to learn more about participating in a clinical trial and why this is an important step in driving research progress:

Clinical Trials and You  English and Spanish

What Are Clinical Trials? English and Spanish

There are many opportunities in Maryland, Virginia, and Washington, DC to participate in a T1D clinical trial close to home. See below for active opportunities. You can also utilize JDRF’s Clinical Trials Connection tool to find additional opportunities.

If you have any questions, please contact one of our Mid-Atlantic Chapter Clinical Trials Education Volunteers Tom Brobson or Sidney Smith.


TrialNet ATG Prevention Study (STOP-T1D) to delay or prevent T1D in people ages 12-35 who have a 50% risk of clinical diagnosis (Stage 3) within two years. (TrialNet STOP-T1D Study Flyer)


The DIAGNODE-3 study is testing an investigational drug called Diamyd (rhGAD65) to see if it is able to preserve the body’s own insulin-producing capacity by halting or delaying the autoimmune attack on the beta cells.

PARTICIPANT AGE: 12 – 29 years old and diagnosed with T1D within the past six months.

LOCATION: Johns Hopkins, Baltimore, MD

CONTACT: Alexis Thomas, diagnode3study@jh.edu or 443-814-9385


Evaluation of the MiniMed 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp
The study is testing how Fiasp works in the new Medtronic 780 G pump. Currently the Medtronic 780 G can only use Humalog or Novolog insulin. The results of this study could expand the insulin options for use in the Medtronic 780 G pump.

PARTICIPANT AGE: 7-80 years old

LOCATION: Baltimore, MD

CONTACT: Denise Reyes, Denise.m.reyes@medtronic.com or 818-576-5323


NAP Study
The UVA Center for Diabetes Technology is seeking individuals with T1D who are 18 years and older for a clinical research study. The purpose of this study is to test the safety of two algorithms (complex mathematical formulas) in development at UVA Center of Diabetes Technology. The Neural Net Implementation (NAP) algorithm attempts to use your past glycemic patterns as well as the history of many other type 1 diabetics glycemic patterns and then suggest glycemic changes. The UVA Model Predictive Control (UMPC) algorithm works when carbohydrate information at a meal is entered into the insulin pump and when it is not entered into the insulin pump. You will be studied at a local hotel for approximately 20 hours per each session. The two hotel sessions can be performed back-to-back during the same hotel stay or in two hotel stays separated up to 28 days. After study enrollment, one week of data will be downloaded from your insulin pump or from your t:connect account to establish your baseline values.


LOCATION: Charlottesville, VA

CONTACT: Morgan Fuller, mf2nu@uvahealth.org or (434) 242-9379


Algorithmic Development, Prototyping, And Pilot Clinical Testing of a Therapy Optimization Platform to Support Healthcare Providers in The Management of Type 2 Diabetes Preliminary Data Collection
UVA Health System Center for Diabetes Technology seeks adults between the ages of 18-80 who have type 2 diabetes to participate in a clinical research study. A study Dexcom G6 Continuous Glucose Monitor (CGM) will be provided to you to use during the study. The purpose of this study is to gather data that will be used to develop a future web-based application that will help doctors take better care of people living with type 2 diabetes. This study will ask for the collection of data that is generated as a part of your normal health care.


LOCATION: Charlottesville, VA

CONTACT: Jasmeen Dhillon, 434-466-7942 or jkd9ud@uvahealth.org


COVID-19 Booster Vaccine Study in People with Type 1 Diabetes
Clinicians from Johns Hopkins are conducting a research study to see if the COVID-19 Booster Vaccine increases glucose levels or insulin requirements in patients with type 1 diabetes.


LOCATION:  Suburban Hospital and Howard County General Hospital Medical Campus


Adapting Diabetes Treatment Expert Systems to Patient’s Expectations and Psychobehavioral Characteristics in Type 1 Diabetes
UVA Center for Diabetes Technology seeks adults ages 18 and up with T1D for a research study to test different ways CGM data can be used to help manage diabetes. This study involves using a Dexcom G6 sensors, and an investigational diabetes application on an Android smart phone. Participants currently using multiple daily injections (MDI) may use a study insulin pump, if desired. There will be weekly surveys to complete, as well as 3 separate blood draws for A1c and lab values. This study will last approximately 7 months and there will be approximately 7 visits. All of these visits can be completed virtually using a web-based video conferencing tool. Study-related Dexcom G6 sensors, transmitters, and infusion sets if applicable will be provided free of charge.


LOCATION: Virtual or in-person in Charlottesville, VA

CONTACT: Emma Emory, EE9M@virginia.edu or 434-982-6479


A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
Read more about this clinical trial and its study site at VCU Medical Center in Richmond, VA here.


Pediatric Boot Camp Program
This program has patients age 11-18 who have been living with T1D for more than one year and have an A1C above 8.5% participate in an intensive 13-week program to improve blood sugar levels. Each week you will meet with your doctor and will use a Dexcom and a smart insulin pen to make insulin dose adjustments and improve blood sugar levels.

PARTICIPANT AGE: Age 11-18 years old

LOCATION: Medstar Georgetown University Hospital, Washington, DC

CONTACT: Barbara Runner, diabetes@georgetown.edu or 202-243-3560 ext 5


Afrezza INHALE-1 Study in Pediatrics (INHALE-1)
This study aims to evaluate the safety and effectiveness of a rapid-acting inhaled insulin product for use in children and teenagers with diabetes.  Qualified participants will either take inhaled insulin for 12 months or continue mealtime injectable insulin for 6 months and then switch to inhaled insulin for the final 6 months. Read more.

PARTICIPANT AGE: 4-17 with type 1 or type 2 diabetes and using mealtime insulin (vial or pen, no pumps)

LOCATION: 39 study locations including Baltimore, MD, Richmond, VA and Wilmington, DE

CONTACT: Call 1-844-INHALE1 or visit https://go.afrezza.com/inhale1


Artificial Pancreas – Adolescent Physiology & Psychology Longitudinal Evaluation (AP APPLE)
UVA Center for Diabetes Technology is recruiting boys and girls who are 11 or 12 years old, going through puberty, and have been diagnosed with T1D for a 2-year research study. The study assesses changes in insulin resistance, glucose response, and psychosocial factors that are related to adolescent T1D management and glycemic control during their pubertal stages. The study requires four in-person visits and 15 phone or email check-in visits and there is $800 compensation for completion of the entire study.


LOCATION: Charlottesville, VA and virtual

CONTACT: Lianna Smith at 434-284-0893 or lhs7px@uvahealth.org




Are you interested in participating in a clinical trial but these aren’t right for you? Check out JDRF’s Clinical Trial Matching Tool, which can potentially match you with a clinical trial. You can also contact one of our Mid-Atlantic Chapter Clinical Trials Education Volunteers Tom Brobson or Sidney Smith.

More from the Mid Atlantic Chapter

Chapter Homepage